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Background: It has been proved that hepatitis B virus (HBV) infection alters the metastatic pattern and affects
survival in colorectal cancer (CRC) and hepatocellular carcinoma (HCC), while the influence of HBV infection on
metastatic pattern and survival in patients with pancreatic cancer (PC) has not been investigated yet.
Methods: We conducted an investigation to evaluate the impact of HBV infection on metastatic pattern and
overall survival in PC. We collected the data of 460 PC patients treated in our hospital from 1999 to 2010. Serum
HBV markers were tested with enzyme-linked immunosorbent assay. The impact of HBV infection on metastatic
pattern and overall survival was analyzed.
Results: We found that the incidence of synchronous liver metastasis was significantly higher in patients with
HBsAg positive than those with HBsAg negative (46.0% vs 32.0%, P < 0.05), and higher in chronic HBV infection
(CHB) group than both non HBV infection and resolved HBV infection group (61.1% vs 33.9%, P < 0.05, and 61.1%
vs 28.7%, P < 0.05, respectively). What’s more, Kaplan-Meier analysis showed that CHB, resolved HBV infection and
non HBV infection group had significant longer overall survival (OS) compared with inactive HBsAg carriers (IC)
group (P=0.037, P=0.009, and P=0.019 respectively). But, in the multivariate analysis, only the CHB and non HBV
infection group had significant better overall survival compared with IC group (P=0.010 and P=0.018 respectively).
Conclusions: Our study found that HBV infection increased synchronous liver metastasis rate, and HBV infection
status was an independent prognostic factor in PC patients.
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Pancreatic cancer (PC) is one of the most aggressive dis-
eases among digestive system malignancies. With both
high incidence and mortality rate, it is responsible for the
fourth leading cause of cancer in the USA [1]. Though less
common in developing countries, the mortality rate of PC
has been keeping increasing in the past decades and
reached the sixth place among all malignancies in China
[2]. Radical surgery, which is the only possible way to cure
the disease, can be conducted in only about 20% patients.* Correspondence: xurh@sysucc.org.cn
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reproduction in any medium, provided the orApproximately 60% patients are found to have metastases
at the time of diagnosis [3]. Palliative treatments, mainly
chemotherapy, radiotherapy, interventional therapy and
immunotherapy, contribute limited survival benefit.
The prevalence of hepatitis B virus (HBV) infection is
common worldwide, while the infection rate is especially
high in some developing countries, including China [4].
It used to be one of the major public health problems
in China, where 58.2% of the population had ever suf-
fered from the infection of HBV in the 1980s. Since the
introduction of universal infant immunization policy, the
HBV carrier rate had dropped from 9.75% in 1992 to
7.18% in 2006 among the general Chinese population [5].
HBV infection has been demonstrated to play an import-
ant role in the development of hepatocellular carcinoma. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been increasing reports about the existence of HBV
in extrahepatic tissues, such as pancreas, kidneys, skin,
bone marrow, colon, lymph nodes, and vessel walls [8,9],
with the manifestation of various severities of extrahepatic
symptoms [10]. Moreover, there’re also investigations indi-
cating that HBV infection is associated with a higher risk
of some extrahepatic malignancies, including PC and non-
Hodgkin’s lymphoma [11-15]. Some studies further
presented a hypothetical mechanism of the development
of PC with HBV infection: a multistep process from pre-
neoplastic pancreatic lesions to invasive cancer resulted
from persistent inflammation in the pancreas caused by
HBV infection [16].
There are some reports available regarding the influ-
ence of HBV infection on metastatic pattern of colorec-
tal cancer (CRC). Interestingly, compared with patients
not infected with HBV, hepatic metastasis rate was
shown to be decreased while the extrahepatic metastasis
rate elevated in patient infected with HBV [17,18], and
in HCC with HBV infection, multiple occurrences hap-
pened more frequently than intrahepatic metastasis [19],
suggesting HBV infection might play an important role
in the progression of some extrahepatic malignancies.
In addition, studies showed that HBV infection also af-
fected the survival of HCC and CRC patients [17,20].
However, the investigation about the impact of HBV in-
fection on metastatic pattern is still blank, and the influ-
ence of different HBV infection status on survival in PC
has not been fully studied. Thus, we embarked on this
study to evaluate whether HBV infection status was asso-
ciated with metastatic pattern and survival in PC.
Materials and methods
Ethics statement
All patients provided written informed consent for their
information to be stored and used in the hospital database.
Study approval was obtained from independent ethics
committees at Cancer Center of Sun Yat-Sen University.
The study was undertaken in accordance with the ethical
standards of the World Medical Association Declaration
of Helsinki.
Study population
Based on the discharge diagnosis, Data of Patients treated
at Sun Yat-sen University Cancer Center in Guangzhou,
China from February 28, 1999 to March 31, 2011 who
were diagnosed with pancreatic adenocarcinoma were
retrospectively collected. 460 histopathologically con-
firmed cases with available test results for HBV infection
were enrolled in the final analysis. 442 cases were ex-
cluded from the study since they were diagnosed with
other types of pancreatic cancer, had no record of patho-
logic or imaging results. According to the HBV infectionstatus at diagnosis, patients were categorized into four sub-
groups. The categorization of the groups was performed
based on the clinical significance of each test index.
Chronic hepatitis B (CHB), which stood for a status of ac-
tive HBV replication, was characterized by HBsAg positive
and at least one of HBeAg and HBV-DNA positive. In-
active HBsAg carriers (IC), meaning current HBV infection
but without active replication, were defined as HBsAg
positive, and both HBeAg and HBV-DNA negative. Re-
solved HBV infection, which indicated previous HBV in-
fection but the virus was already eliminated, was featured
by HBsAg negative and at least one of anti-HBe and anti-
HBc positive. Non HBV infection, which meant no history
of HBV infection judging from the serum test result, and
referred to HBsAg, HBeAg, HBV-DNA, anti-HBe and
anti-HBc negative, regardless of the status of anti-HBs
[21,22]. A further categorization organize patients into two
groups, HBsAg positive group (CHB+IC), and HBsAg
negative group (resolved HBV infection +non HBV infec-
tion). Additionally, Informed consent to receive a test for
HBV infection was obtained at the first visit of all patients,
and the research was approved by the Ethics Committee of
Sun Yat-sen University Cancer Center.
Serologic assay for HBV infection
Blood samples were collected at the first visit of all the
patients, and serum samples were separated for the test
of HBV infection. Enzyme-linked immunosorbent assay
was applied to the tests of hepatitis B surface antigen
(HBsAg), hepatitis B surface antibody (anti-HBs), hepatitis
B e antigen (HBeAg), hepatitis B e antibody (anti-HBe)
and hepatitis B core antibody (anti-HBc). Polymerase
chain reaction was used to detect HBV deoxyribonucleic
acid (HBV-DNA). The quality of the tests was controlled
by timeliness of the tests, and qualified positive and nega-
tive control serum.
Assessment of metastases, treatment and follow-up of
patients
All patients received chest, abdominal and pelvic com-
puted tomography (CT) or magnetic resonance imaging
(MRI) before surgery or chemotherapy, and the metastatic
status were evaluated by imaging specialists. For those who
underwent surgery, additional evaluations were given by
surgeons. Thus accurate information with regard to syn-
chronous liver and extrahepatic metastasis was obtained.
Therapeutic and follow-up schedules were established and
implied referring to the NCCN Clinical Practice Guidelines
of pancreatic cancer.
Statistical analysis
The statistical analyses were performed with SPSS for
Windows V.13.0. A two tailed p value <0.05 was considered
statistically significant. Differences of baseline parameters
Table 1 Comparison of baseline characteristics between


















TNM stage (AJCC) 63(100) 397(100)
0.08
Ia + Ib 1(1.6) 5(1.3)
IIa + IIb 11(17.5) 106(26.7)
III 12(19.0) 86(21.7)
IV 39(61.9) 200(50.3)
















HBsAg positive group: chronic HBV infection (CHB) group + inactive HBsAg
carriers (IC) group. HBsAg negative group: resolved HBV infection + non HBV
infection group.
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ated by chi-square test, Student t test or Kruskal-Wallis H
test based on the type of the data and comparison. Overall
survival (OS) was the time interval from the date of diag-
nosis to death from PC or to the last date of follow-up.
Overall survival (OS) curves were plotted with the
Kaplan-Meier method, and differences were compared
with log-rank test. A Cox regression was used for univari-
ate and multivariate analysis. Hazard ratio (HR) and 95%
confidence interval (95% CI) were computed with the Cox
proportional-hazards model. Variables significantly prog-
nostic in the univariate analysis were selected for the mul-
tivariable analysis using the forward stepwise method.
Results
Baseline characteristics
A total of 460 cases were qualified for the analyses.
Among them, CHB, which means active HBV replica-
tion, was identified in 18 patients (3.9%). IC, which indi-
cates HBV in the body without active replication, was
identified in 45 patients (9.8%). resolved HBV infection,
which represents previous HBV infection but the viruses
have already been eliminated, was identified in 143 pa-
tients (31.1%). non HBV infection, which is the mark of
the no history of HBV infection status, was identified in
254 patients (55.2%). Thus, 63 (13.7%) patients were en-
rolled in HBsAg positive group (CHB +IC), and 397
(86.3%) patients were classified into HBsAg negative
group (resolved HBV infection + non HBV infection).
The comparisons of baseline characteristics were listed
in Table 1. No significant difference was found between
HBsAg positive and negative group in age, tumor stage,
tumor size, operation status and chemotherapy rate
(Table 1). While the HBsAg positive group manifested
with a significant male and young-aged predominance
compared with the HBsAg negative group.
Synchronous liver, extrahepatic and general metastasis
Synchronous liver metastasis was found in 156 (33.9%)
patients. There were 11 (61.1%) cases of synchronous
liver metastasis in CHB group, 18 (40.0%) cases in IC
group, 41 (28.7%) cases in resolved HBV infection group,
and 86 (33.9%) cases in non HBV infection group. Thus
29 (46.0%) were identified out of 63 cases in HBsAg
positive group, and 127 (32.0%) out of 397 cases in
HBsAg negative group, the incidence of synchronous
liver metastasis was significantly higher in HBsAg posi-
tive group compared with HBsAg negative group
(46.0% vs 32.0%, P = 0.03). As for extrahepatic metas-
tasis, 8 cases were confirmed in HBsAg positive group
and 72 in HBsAg negative group. There was no significant
difference in the synchronous extrahepatic metastasis rate
between the two groups (12.7% vs 18.1%, P = 0.29). In
addition, no significant difference was found in generalsynchronous metastasis between HBsAg positive and
negative group (55.6% vs 42.8%, P = 0.06). Detailed infor-
mation was shown in Table 2.
We further explored the influence of HBV infection
on synchronous metastatic pattern in PC by classifying
cases into more subgroups for comparisons (Table 2).
No significant difference was identified between patients
with the history of HBV infection (CHB + IC + resolved
HBV infection) and those without (non HBV infection).
Among the Comparisons between HBV infection sub-
groups (CHB, IC, and resolved HBV infection) and non
HBV infection group, and comparisons among HBV in-
fection subgroups, the synchronous liver metastasis rate
was significantly higher in CHB group than non HBV in-
fection or resolved HBV infection group (61.1% vs
33.9%, P = 0.02, and 61.1% vs 28.7%, P = 0.01), and the
incidence of general metastasis in CHB group was
Table 2 Influence of HBV infection on metastatic pattern in PC







Yes No Yes No Yes No
HBsAg positive group vs
HBsAg negative group
HBsAg positive (63) 29 (46.0) 34 (54.0) 0.03 8 (12.7) 55 (87.3) 0.29 35 (55.6) 28 (44.4) 0.06
HBsAg negative (397) 127 (32.0) 270 (68.0) 72 (18.1) 325 (81.9) 170 (42.8) 227 (57.2)
HBV infection group vs non
HBV infection group
CHB +IC +resolved HBV
infection (206)
70 (34.0) 136 (66.0) 0.98 32 (15.5) 174 (84.5) 0.34 90 (43.7) 116 (56.3) 0.73
Non HBV infection (254) 86 (33.9) 168 (66.1) 48 (18.9) 206 (81.1) 115 (45.3) 139 (54.7)
Comparisons between HBV
infection subgroups and
non HBV infection group
CHB (18) 11 (61.1) 7 (38.9) 0.02 2 (11.1) 16 (88.9) 0.61 12 (66.7) 6 (33.3) 0.08
Non HBV infection (254) 86 (33.9) 168 (66.1) 48 (18.9) 206 (81.1) 115 (45.3) 139 (54.7)
IC (45) 18 (40.0) 27 (60.0) 0.43 6 (13.3) 39 (86.7) 0.37 23 (51.1) 22 (48.9) 0.47
Non HBV infection (254) 86 (33.9) 168 (66.1) 48 (18.9) 206 (81.1) 115 (45.3) 139 (54.7)
Resolved HBV infection
(143)
41 (28.7) 102 (71.3) 0.29 24 (16.8) 119 (83.2) 0.60 55 (38.5) 88 (61.5) 0.19
Non HBV infection (254) 86 (33.9) 168 (66.1) 48 (18.9) 206 (81.1) 115 (45.3) 139 (54.7)
Comparisons among HBV
infection subgroups
CHB (18) 11 (61.1) 7 (38.9) 0.13 2 (11.1) 16 (88.9) 1.00 12 (66.7) 6 (33.3) 0.26
IC (45) 18 (40.0) 27 (60.0) 6 (13.3) 39 (86.7) 23 (51.1) 22 (48.9)
Resolved HBV infection
(143)
41 (28.7) 102 (71.3) 0.15 24 (16.8) 119 (83.2) 0.58 55 (38.5) 88 (61.5) 0.13
IC (45) 18 (40.0) 27 (60.0) 6 (13.3) 39 (86.7) 23 (51.1) 22 (48.9)
CHB (18) 11 (61.1) 7 (38.9) 0.01 2 (7.7) 16 (92.3) 0.78 12 (66.7) 6 (33.3) 0.02
Resolved HBV infection
(143)
41 (28.7) 102 (71.3) 24 (11.9) 119 (88.1) 55 (38.5) 88 (61.5)
CHB, chronic HBV infection, IC, inactive carriers.
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HBV infection group (66.7% vs 38.5%, P = 0.02). Because
no significant difference was found in extrahepatic metas-
tasis between CHB and resolved HBV infection group, the
difference showed in general metastasis rate might be
explained by increased liver metastasis, and has nothing
to do with extrahepatic metastasis. In addition, none of
the comparisons in synchronous extrahepatic metastasis
reached significant difference.
Follow-up and survival
The mean and median follow-up time after discharge
from hospital were 11.4 months and 6.5 months respect-
ively, ranging within 0.1-139.4 months. 17 cases out of
18 cases in CHB group, 41 cases out of 45 cases in IC
group, 123 cases out of 143 cases in resolved HBV infec-
tion group and 217 cases out of 254 cases in non HBV
infection group were available of overall survival infor-
mation, and were qualified for survival analysis com-
pared with the log-rank test. The estimated general
median OS time of PC was 7.6 months. In the univariate
analysis exploring the influence of HBV infection status
on OS in PC (Table 3), CHB, resolved HBV infection
and non HBV infection group had significantly longer
OS compared with IC group (P=0.037, P=0.009, and
P=0.019 respectively). While, in the multivariate analysisadjusted by variables significantly prognostic in univari-
ate analysis, only the CHB and non HBV infection group
had significant better overall survival compared with IC
group (P=0.010 and P=0.018 respectively, Table 4). The
survival curves of CHB vs IC, resolved HBV infection vs
IC and non HBV infection group vs IC plotted with
Kaplan-Meier method were presented in Figure 1 and
Figure 2.
Discussion
Our research found that the incidence of synchronous
liver metastasis of pancreatic cancer (PC) was higher in
patients with HBsAg positive than those negative, while
no significant difference of extrahepatic metastasis was
found between the two groups. Compared with non
HBV infection group, only chronic hepatitis B (CHB)
group was demonstrated to have significant higher rate
of liver metastasis, which indicated that HBV infection
with active replication had the greatest influence on liver
metastasis of PC. What’s more, CHB and non HBV in-
fection group showed significant better overall survival
than IC group, indicating HBV infection status to be an
independent prognostic factor in PC patients.
There were mounts of studies investigating the impact
of HBV infection on metastatic patterns of other malig-
nancies. Incidence of liver metastasis was demonstrated
Table 3 Association between prognostic factors, HBV infection and overall survival in a univariate analysis
Factors Number Overall survival
Hazard ratio (95% confidence interval) P value
Age (≤ 70 yr/> 70 yr) 347/51 1.399 (1.015-1.927) 0.039
Gender (Male/Female) 268/130 0.822 (0.644-1.051) 0.117
Pretherapeutic weight loss (No/Yes) 150/248 1.282 (1.014-1.620) 0.037
The 7th tumor-node-metastasis (TNM) staging (AJCC) (Ia + Ib/IIa + IIb/III/IV) 5/100/86/207 1.339 (1.169-1.534) < 0.001
Degree of differentiation (Poorly differentiated or mucinous adenocarcinoma/
Moderate differentiated/Well differentiated)
224/130/44 0.666 (0.540-0.822) < 0.001
Surgery (No/Yes) 228/170 0.522 (0.413-0.660) < 0.001
Surgery (radical surgery R0 resection/radical surgery R1 resection/radical surgery
R2 resection or Bypass or stent only or exploration or none)
54/4/112 1.410 (1.151-1.727) 0.001
Chemotherapy (No/Yes) 219/179 0.694 (0.552-0.873) 0.002
Baseline CA199 (Normal/Elevated) 80/297 1.614 (1.208-2.156) 0.001
Body mass index (≤ 25/> 25) 362/36 0.802 (0.533-1.209) 0.291
Smoking (No/Yes) 270/126 1.003 (0.791-1.272) 0.981
Alcohol consumption (No/Yes) 315/80 1.183 (0.901-1.552) 0.225
HBV infection
HBsAg positive/HBsAg negative 58/340 1.285 (0.943-1.749) 0.110
Non HBV infection/CHB +IC +resolved HBV infection 217/181 1.010 (0.807-1.266) 0.928
Non HBV infection/CHB 217/17 0.776 (0.432-1.394) 0.394
Non HBV infection/IC 217/41 1.538 (1.072-2.208) 0.019
Non HBV infection/RHB 217/123 0.923 (0.714-1.193) 0.541
CHB/IC 17/41 2.060 (1.044-4.064) 0.037
Resolved HBV infection/IC 123/41 1.681 (1.137-2.486) 0.009
Resolved HBV infection/CHB 123/17 0.862 (0.471-1.578) 0.629
Hazard ratios and 95% confidence intervals were calculated with the Cox proportional-hazards model. P value was worked out by Kaplan-Meier method with log-rank test.
CHB, chronic HBV infection, IC, inactive carriers.
Table 4 Association between prognostic factors, HBV





Age (≤ 70 yr/> 70 yr) 1.527 (1.075-2.169) 0.018
The 7th tumor-node-metastasis (TNM)
staging (AJCC) (Ia + Ib/IIa + IIb/III/IV)
1.310 (1.129-1.520) < 0.001





Surgery (No/Yes) 0.553 (0.429-0.713) < 0.001
Chemotherapy (No/Yes) 0.648 (0.506-0.829) 0.001
Baseline CA199 (Normal/Elevated) 1.602 (1.179-2.176) 0.003
HBV infection 0.038
IC 1 (reference)
CHB 0.414 (0.213-0.807) 0.010
Resolved HBV infection 0.683 (0.450-1.036) 0.073
Non HBV infection 0.630 (0.429-0.925) 0.018
CHB, chronic HBV infection, IC, inactive carriers.
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significantly increased in colorectal cancer (CRC) pa-
tients with HBV infection than non-infection ones, and
significance of the difference existed in all status of HBV
infection, including CHB, IC, and resolved HBV infec-
tion [18]. This impact had nothing to do with coexisting
liver injury [17]. In hepatocellular carcinoma (HCC) with
HBV infection, multiple occurrences happened more fre-
quently than intrahepatic metastasis [19]. To date, our
study was the first report about influence of HBV infec-
tion on metastatic pattern of PC. We found that com-
pared with non HBV infection group, only chronic HBV
infection group (CHB) showed a significant higher liver
metastasis rate. Thus, it can be concluded that the im-
pacts of HBV infection on liver metastasis vary in differ-
ent malignancies. Tumor progression was pushed by
intrinsic mutations and influenced by the microenviron-
ment [23]. Although before tumor cell implantation, the
microenvironment in the liver might share much simi-
larity, the differences of tumor intrinsic properties and
the microenvironment nurtured by the interaction
Figure 1 Comparison of overall survival between chronic HBV infection (CHB) and inactive HBsAg carriers (IC) group. In the Kaplan-Meier
analysis compared with log-rank test, CHB group had a significant longer overall survival than IC group (P=0.037).
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implantation would result in discriminated outcomes.
Besides, HBV infection had been proved to be one of the
risk factors in PC [11,12], and HBV DNA and antigens
were identified in PC tissues [24]. Moreover, both liver
and pancreas progenitors had the same origin of the
endoderm cells in the embryonic foregut [25,26], and
the two organs shared the same conduct for external se-
cretion and blood vessels. It was reasonable to postulate
that the current understanding of the relationship be-
tween liver, pancreas, and HBV infection was only a tip
of the iceberg. It was also reasonable to assume that de-
veloped from an HBV infected microenvironment with
persistent inflammation, PC cells might have a predilec-
tion for the analogous hepatic nest infected with HBV.
Furthermore, HBV proteins were able to trigger the self-
maintaining and amplifying looped generation of certain
cytokines in liver, such as prostaglandin E2 (PGE2) and
growth factors, which activated cell signal pathways, and
promoted growth of cancer cells [27,28]. While current
study concentrating on the correlation between HBV
and PC were mainly restricted in epidemiologic investi-
gation and carcinogenesis mechanism, regarding HBV
infection as a risk factor of PC, perhaps further attention
should also be paid to understand how HBV infection
affects PC progression.
HBV infection was proved to have more or less influ-
ence on survival in some malignancies. Hatanaka K,
et al. found the survival of HCC patients infected withHBV to be the poorest compared with patients infected
with HCV or non HBV/HCV [20]. In terms of CRC, pre-
vious studies didn’t reach consistent conclusion about the
survival impact of HBV infection [17,18,29]. Concerning
the impact of HBV infection on PC in our study, both
CHB and non HBV infection group had significantly lon-
ger OS compared with IC group in multivariate analysis.
It was interesting that different HBV infection status
showed differences in the overall survival in PC patients.
The results that patients infected with actively replicative
HBV (CHB group) showed better survival than inactive
HBsAg carriers (IC group), and patients classified into
resolved HBV infection had no significant OS difference
compared with inactive HBsAg carriers (IC group) might
seem to be somewhat confusing. Here we listed some
explanation for the results of survival analysis in our
research.
Firstly, HBV antigens might influence the overall sur-
vival in PC patients. Some previous studies gave us
clues. HBsAg, which existed in CHB and IC groups, was
found to down-regulate the production of interleukin-12
(IL-12), a cytokine which was identified to possess the
anti-cancer power [30]. However, the expression of
HBeAg in liver cells was demonstrated to be associated
with more serious liver cell damage, and enhanced pro-
duction of inferferon (IFN)-gamma [31,32]. Considering
the HBeAg expression was also demonstrated to exist in
PC tissues with HBV infection [24], such mechanism
might likewise contribute to anti-pancreatic cancer cell
Figure 2 Comparison of overall survival between non HBV infection and inactive HBsAg carriers (IC) group. In the Kaplan-Meier analysis
compared with log-rank test, non HBV infection group had a significant longer overall survival than IC group (P=0.019).
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(with both HBeAg and HBsAg positive) showed better
survival than IC group (with HBsAg positive and HBeAg
negative), although patients in CHB group had active
HBV proliferation, which might bring liver dysfunction
and make patients’ condition worse. It could also partly
explain why IC group showed worse survival than non
HBV infection group.
Secondly, starting from the time they received chemo-
therapy, patients with active HBV infection in our center
were routinely given anti-HBV therapy to control the ac-
tivation of HBV and prevent the outbreak of hepatitis B
virus. Anti-HBV drugs were shown to have immunoreg-
ulatory effects [33] and might also influence the anti-
cancer effectiveness of the immune system.
Thirdly, HBV was hepatotrophic virus and active HBV
replication in liver cells triggered the immune response,
mainly cellular immunity, which induced the death of
liver cells and caused hepatic fibrosis. Because HBV was
also demonstrated to be existed in PC tissues, such im-
mune response acted on liver cells might also work on
pancreatic cancer cells. Here we would like to share a
case reported by Fujimoto, K, et al. They reported a case
of complete remission of splenic marginal zone lymph-
oma after an acute flare-up of hepatitis B in a hepatitis B
virus carrier [34]. There were studies finding HBV to be
a risk factor for non-Hodgkin lymphoma, and HBV in-
fection was also found to be existed in B-cell non-
Hodgkin lymphoma tissues [35]. The case reportedmight be an extreme example of the possible mechanism
we listed above to kill the cancer cells in which HBV
replicate actively.
Last but not the least, patients in resolved HBV infec-
tion group and IC group showed no significant differ-
ence in OS. This conclusion was hard to explain since
patients in resolved HBV group might possess a more ef-
fective immune system, thus shall have a better survival
than patients in IC group. Because the P value (0.073) in
the multivariate analysis of “resolved HBV group vs IC
group” was quite close to the cut point of 0.05 we set
and the sample size for survival analysis was relatively
small (41 for IC group, and 123 for resoled HBV infec-
tion group), there was a possibility that our research didn’t
reach the existed difference between the two groups. But,
there were also possible small number of inactive HBV in-
fection cases in the “resolved HBV infection” group we de-
fined according to the serum test result, depending on the
sensitivity of the serum test for HBV infection, and they
might confound the result of survival analysis between the
two groups.
To summarize, the mechanism of how different HBV
infection status affect the progression of PC was still not
clear, more researches about the clinical data and labora-
tory mechanism are both needed.
There were some limitations in our study. To start
with, our data was retrospectively collected from medical
records, considering inevitably missed information about
progress free survival (PFS) and disease free survival
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into analysis. In addition, we investigated the impact of
HBV infection only on synchronous metastasis, owning to
our concern about imprecision of the information about
metachronous metastasis. However, the information about
synchronous metastasis was qualified, because we col-
lected it from the medical records of first visit of patients,
for each of them, a chest, abdominal and pelvic CT or
MRI were conducted and evaluated by imaging specialists,
and those underwent surgery were further evaluated by
surgeons during operations. What’s more, we enrolled PC
patients in all tumor stages, which was an aggregation of
PC patients with metastasis all along the disease progress,
thus the result of our study was in line with the metastasis
status of general PC population. Last but not least, al-
though we collected cases from the time duration of more
than 10 years, the number of cases in each group was still
limited, more data and work are needed in future.
In conclusion, our study discovered that the incidence
of liver metastasis in PC patients with HBsAg positive
was higher than those with HBsAg negative. Compared
with patients with no history of HBV infection and those
with resolved HBV infection, chronic HBV infection
promoted liver metastasis in PC. What’s more, patients
with chronic HBV infection and non HBV infection had
significantly better overall survival compared with in-
active HBsAg carriers in pancreatic cancer.
Conclusion
Our study was the first to find HBV infection increased
liver metastasis rate and the status of HBV infection was
an independent prognostic factor in pancreatic cancer.
Since the existing studies investigating the relationship
between HBV infection and pancreatic cancer mainly
regarded HBV infection as a risk factor, our work sug-
gested that more investigations should focus on the impact
of HBV infection on progression in pancreatic cancer.
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